Medifast Sees Q3 EPS $(0.70)-$(0.05) vs $(0.52) Est., Revenue $125M-$145M vs $161.8M Est.
Portfolio Pulse from Benzinga Newsdesk
Medifast has released its Q3 earnings guidance, projecting an EPS range of $(0.70)-$(0.05), which is below the estimated $(0.52). The company also expects revenue between $125M and $145M, significantly lower than the estimated $161.8M.
August 05, 2024 | 8:38 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Medifast's Q3 earnings guidance is below expectations, with EPS projected between $(0.70) and $(0.05) compared to the estimated $(0.52). Revenue is also expected to be significantly lower, ranging from $125M to $145M against the $161.8M estimate.
The lower-than-expected EPS and revenue guidance indicate potential financial struggles or market challenges for Medifast, likely leading to a negative short-term impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100